Microfluidic Biochips Patents: Top Companies & Filing Trends 2026
- Filings have cooled since the 2019 peak of 150. the latest full year sits well below that high, with 2026 still partial — a maturing claim landscape rather than a growing one.
- B01L lab apparatus claims dominate at 1,272 of 1,674 families. while MEMS-classified B81B filings trail at just 128, marking where structural integration claims are thinner.
- The United States receives more filings than Europe, WIPO, China, India and Australia combined at the next tier. with 641 records, concentrating litigation and freedom-to-operate risk in one jurisdiction.
Filing growth compares 2021 (107 records) with 2024 (80) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,674 records in scope (CR5), not by the ranked leaders only.
A field built on channel geometry, droplet control and surface chemistry
Microfluidic biochips and lab-on-chip devices route, mix and analyze fluids at sub-millimeter scale, and the patent record reflects three recurring claim types: channel fabrication, droplet generation and flow control, and surface functionalization for binding or separation. The search corpus spans 1,674 patent families filed from 2017 onward, classified predominantly under B01L lab apparatus and G01N material analysis codes, with smaller but persistent activity in bioreactor (C12M) and nucleic-acid testing (C12Q) subclasses.
Because publication typically lags filing by around 18 months, the drop-off visible in the most recent one or two years understates real filing activity rather than confirming a slowdown. The more reliable signal is the shape of the curve from 2017 through the 2019 peak and its subsequent decline toward the 2022 midpoint, which points to a field where core claim territory is largely staked out and later entrants are filing narrower, more defensive improvements.
Filing trend and technology composition
Publication counts by year and by IPC subclass, drawn from the full 1,674-family dataset covering 2015 through the July 2026 cut-off.
A peak in 2019, then a plateau and decline
Filings rose to 105 in 2017 and peaked at 150 in 2019, before easing toward 121 at the 2022 midpoint and continuing down to 15 in the still-partial 2026 count. Read the most recent one to two years as undercounted rather than as a genuine collapse in activity.
B01L and G01N carry the bulk of the claim volume
B01L lab apparatus classifications appear in 1,272 records and G01N material analysis in 1,009, together accounting for the great majority of filings. C12M bioreactor claims (377) and C12Q enzyme/DNA testing claims (300) form a secondary tier, while B81B MEMS structural claims (128), C12N microorganism claims (118), B01J catalysis claims (107) and C40B combinatorial library claims (62) are comparatively thin — a signal of where structural and library-scale integration is less contested.
Shares are the percentage of the 1,674 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Microfluidic Biochips and Lab-on-Chip with Eureka
This page is one run against one query. Ask Eureka your own question about microfluidic biochips and lab-on-chip and every answer comes back with the patent numbers behind it.
Try EurekaThe documents that anchor this field
Microfluidic chip, droplet generation device and method for controlling droplet generation size
The disclosure covers a microfluidic chip and droplet generation device in which a first flow channel carrying a dispersed phase and a second flow channel carrying a continuous phase intersect a third flow channel at a confluence area, forming droplets whose size is controlled through the geometry and flow relationship of the three channels.Filed by BOE Technology Group, published 2024-08-22 — illustrates the continued refinement of droplet-generation geometry rather than a new fabrication approach.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20040053290A1 | Devices and methods for biochip multiplexing | 630 |
| 2 | US20050053952A1 | Microfluidic nucleic acid analysis | 367 |
| 3 | US6939451B2 | Microfluidic chip having integrated electrodes | 347 |
| 4 | US20050221281A1 | Self-contained microfluidic biochip and apparatus | 338 |
| 5 | US6355491B1 | Individually addressable micro-electromagnetic unit array chips | 320 |
| 6 | US7172897B2 | Devices and methods for biochip multiplexing | 261 |
| 7 | WO2005010543A1 | On-chip magnetic sensor device with suppressed cross-talk | 259 |
| 8 | WO2005010542A2 | On-chip magnetic particle sensor with improved snr | 240 |
| 9 | WO2002024322A2 | Microfluidic chip having integrated electrodes | 234 |
| 10 | US20050032240A1 | Microfluidic devices for controlled viscous shearing and formation of amphiphilic vesicles | 202 |
Citation counts accumulate over time and favor older filings; treat them as a measure of influence on later work, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern says about the field's maturity
Three signals stand out once the raw counts are read against filing behaviour rather than taken at face value.
Core claim territory is largely staked
The run-up from 105 filings in 2017 to a peak of 150 in 2019, followed by a steady decline through the 2022 midpoint of 121, describes a field where foundational channel and droplet-control claims were filed early. New entrants now compete on narrower improvements rather than open claim space.
Lab-apparatus claims dominate the corpus
Three in four records in this dataset touch B01L lab-apparatus classifications, with G01N material-analysis claims layered on top of most of them. Filing into this combination means competing directly with the densest prior art in the field.
US filings set the freedom-to-operate baseline
The United States receives close to double the filings of the next office, Europe, with WIPO PCT filings a further step behind and China, India and Australia trailing. A clearance search that skips the US corpus misses the largest single share of enforceable claims.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to microfluidic biochips and lab-on-chip, with the prior art for and against each one.
A dispersed field with a handful of repeat filers
Recent-year momentum is low across even the more active assignees, and co-assignee activity is concentrated in a small number of corporate-family pairs rather than broad industry alliances.
Even the most active assignee has slowed
The University of California Board of Regents recorded only two filings in the latest year, the highest recent-year count among tracked assignees; BOE Technology Group, IBM, Canada's National Research Council and Case Western Reserve University each recorded none in the same period.
Collaboration clusters around corporate-family filings
The strongest co-assignee pairs link a company to its own subsidiary or a named inventor rather than to an external partner, with the top pairing recorded 14 times and the next two BOE-affiliated pairings at 13 and 12. This points to internal group-company filing structures more than cross-industry joint development.
A long tail behind a few academic and corporate names
Universities and research institutes such as Caltech, Johns Hopkins and Canada's National Research Council appear alongside corporate filers such as BOE Technology Group, IBM and Pattern Bioscience, suggesting the field still draws meaningfully from academic labs rather than being fully consolidated into industry.
| Assignee | Recent year | YoY |
|---|---|---|
| The Regents of the University of California | 2 | — |
| BOE Technology Group Co., Ltd. | 0 | — |
| International Business Machines Corporation (IBM) | 0 | — |
| National Research Council of Canada | 0 | — |
| Case Western Reserve University | 0 | — |
| PATTERN BIOSCIENCE INC | 0 | — |
| Tenglong Technology Co., Ltd. | 0 | — |
| California Institute of Technology (Caltech) | 0 | — |
Where to take this analysis
The trend and assignee data point to specific next steps depending on whether the goal is clearance, licensing or R&D scoping.
Run a freedom-to-operate check on the thin subclasses
B81B, C12N, B01J and C40B classifications carry far fewer filings than B01L and G01N. Before committing to a MEMS-integrated or combinatorial-library design, check whether that lighter density reflects genuine white space or simply narrower claim drafting.
Explore IPC subclasses in EurekaTrack the BOE and University of California filing lines
BOE Technology Group's recent droplet-generation filing and the University of California's continued recent-year activity are the two most active current signals in an otherwise quiet field. Both are worth monitoring for follow-on continuations.
Follow assignee activity in EurekaVerify citation-heavy patents' current legal status
The most-cited records in this corpus date back to the early-to-mid 2000s. High citation counts confirm influence on later filings, not that the underlying claims remain in force — check expiry and maintenance status before treating them as a blocking risk.
Check patent status in EurekaCommon questions about microfluidic biochip patents
The dataset shows a dispersed field rather than one dominated by a single owner. Corporate filers such as BOE Technology Group, IBM and Pattern Bioscience appear alongside university and research-institute assignees including Caltech, Johns Hopkins, Case Western Reserve and Canada's National Research Council. Recent-year filing counts are low across all of them, with the most active recent filer, the University of California Board of Regents, recording only two filings in the latest tracked year, so no single assignee currently shows dominant filing momentum.
Filing activity peaked in 2019 at 150 records and has declined since, sitting at 121 by the 2022 midpoint and much lower in the most recent, still-incomplete years. Because publication typically lags filing by around 18 months, the very latest years will rise as more filings publish, but the multi-year trend from the 2019 peak through 2022 already points to a flattening or declining filing rate rather than continued growth.
B01L, covering laboratory apparatus, appears in 1,272 of the 1,674 records and is the dominant classification, closely followed by G01N material-analysis and testing claims at 1,009. Secondary classifications include C12M bioreactor apparatus and C12Q enzyme or nucleic-acid testing claims. Anyone drafting new claims in this space should expect the densest prior art in the B01L and G01N combination, with comparatively lighter coverage in B81B MEMS-structural and C40B combinatorial-library codes.
The IPC composition data points to MEMS-structural integration (B81B, 128 records), catalytic microreactor processes (B01J, 107 records) and combinatorial library applications (C40B, 62 records) as the thinnest major branches relative to the core lab-apparatus and material-analysis codes. That relative thinness does not guarantee an easy filing, since some of it may reflect narrower technical scope rather than open opportunity, but it is the right starting point for a targeted freedom-to-operate search before committing to a design direction.
The United States is the single largest receiving office in this dataset with 641 records, ahead of the European Patent Office at 311 and WIPO PCT filings at 222; China, India and Australia follow at lower volumes. A clearance search limited to one non-US jurisdiction will miss the largest concentration of filed claims, so US coverage should be the baseline for any freedom-to-operate review in this field.
Research Microfluidic Biochips and Lab-on-Chip in depth with Eureka
Go past this page: query the whole microfluidic biochips and lab-on-chip corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.